Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | METAP2 | P50579 | 3/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 5/20 | 0.35 |
| ▸ | KCNN4 | O15554 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 7/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | RAC2 | P15153 | 1/20 | 0.32 |
| ▸ | RAC3 | P60763 | 1/20 | 0.32 |
| ▸ | CDC42 | P60953 | 1/20 | 0.32 |
| ▸ | RAC1 | P63000 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23911727 | 0.89 | KDM4E (0.46) | KDM4EATML3MBTL1MAPTRAC2 | |
| SCHEMBL23911737 | 0.83 | KDM4E (0.36) | KDM4EATML3MBTL1CYP1A2METAP2 | |
| SCHEMBL23431270 | 0.82 | LMNA (0.33) | MAPTCNR2 | |
| SCHEMBL23911722 | 0.81 | CNR2 (0.31) | CNR2 | |
| SCHEMBL10449450 | 0.78 | CYP1A2 (0.52) | KDM4EATML3MBTL1CYP1A2METAP2 | |
| SCHEMBL15153878 | 0.78 | CYP1A2 (0.52) | KDM4EATML3MBTL1CYP1A2METAP2 | |
| SCHEMBL17614686 | 0.77 | KDM4E (0.46) | KDM4EATML3MBTL1CYP1A2METAP2 | |
| SCHEMBL12792102 | 0.77 | KDM4E (0.53) | KDM4EATML3MBTL1CYP1A2NPSR1 | |
| SCHEMBL22606852 | 0.77 | KDM4E (0.39) | KDM4EATML3MBTL1CYP1A2METAP2 | |
| SCHEMBL29512119 | 0.77 | KDM4E (0.39) | KDM4EATML3MBTL1CYP1A2METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220020937-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2022-01-20 | — | — | US | disclosed |
| US-11145823-B2 | Heterocyclic compound and organic light emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2021-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11145823-B2 | Heterocyclic compound and organic light emitting device including the same | TRPC1, ODC1, DDT | KDM4E 1975/4885ATM 4697/4885L3MBTL1 138/4885 |
| US-20220020937-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | TRPC1, ODC1, DDT | KDM4E 1600/4885ATM 4676/4885L3MBTL1 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.